Multisystem Inflammatory Syndrome in Children—United States, February 2020–July 2021
Clinical Infectious Diseases2021Vol. 75(1), pp. e1165–e1175
Citations Over TimeTop 1% of 2021 papers
Allison D. Miller, Laura D. Zambrano, Anna R Yousaf, Joseph Y. Abrams, Lu Meng, Michael Wu, Michael Melgar, Matthew E. Oster, Shana E Godfred Cato, Ermias D. Belay, Angela P. Campbell, MIS-C Surveillance Authorship Group, Gloria E Anyalechi, Anna Bowen, Tuyen Do, Paul A. Gastañaduy, Katherine Lindsey, Sancta B. St. Cyr, Ramandeep Kaur, Xandy Peterson Pompa, Chloe E. Le Marchand, Jason Robert C Singson, Shannon C O’Brien, Ann Schmitz, Carola I Torres Díaz, Walaa M Elbedewy, Melissa Tobin‐D’Angelo, Heather D. Reid, Marielle Fricchione, Sara Hallyburton, Gillian Richardson, Julie Hand, Dylan Leach, Cole Burkholder, Sarah Lim, Deepam Thomas, Donna L. Gowie, Elizabeth Dufort, Ellen H. Lee, Ayotola Falodun, Courtney Dewart, Zachary J Colles, Jennifer L. Wallace, LaKita D Johnson, Kristina L Herring, Andrea R Liptack
Abstract
Over the first 3 pandemic waves of MIS-C in the United States, cardiovascular complications and clinical outcomes including length of hospitalization, receipt of ECMO, and death decreased over time. These data serve as a baseline for monitoring future trends associated with SARS-CoV-2 B.1.617.2 (Delta) or other variants and increased COVID-19 vaccination among children.
Related Papers
- → Chilblain‐like lesions after BNT162b2 mRNA COVID‐19 vaccine: a case report suggesting that ‘COVID toes’ are due to the immune reaction to SARS‐CoV‐2(2021)26 cited
- → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
- → ОПЫТ ИССЛЕДОВАНИЯ СЕРОПРЕВАЛЕНТНОСТИ К ВИРУСУ SARS-CoV-2 НАСЕЛЕНИЯ ИРКУТСКОЙ ОБЛАСТИ В ПЕРИОД ВСПЫШКИ COVID-19(2020)2 cited
- → Особенности сахароснижающей фармакотерапии у пациентов с SARS-CoV-2 (COVID-19)(2021)